Target intelligence / Profile preview

Cytomegalovirus phosphoprotein 65 (pp65) peptide presented by HLA-A02:01 (CMV pp65/HLA-A02:01)

Target: CMV pp65/HLA-A*02:01

Overview

The CMV pp65-derived peptide presented by HLA-A*02:01 is a major immunodominant epitope of the Human Cytomegalovirus (HCMV). The pp65 protein (UL83) is a primary component of the viral tegument and is highly expressed during the early stages of viral replication (UniProt: P}

Other names: NLVPMVATV-HLA-A*02:01 complexCMV pp65(495-503) peptide-MHCUL83 peptide-HLA-A*02:01pMHC complex (pp65/HLA-A*02:01)CMV pp65-A2 complex

Biological functions

Antigen presentationImmune responseT-cell activationViral recognition

Biomarkers

HLA-A*02:01 genotypeCMV seropositivitypp65 antigenemiaCMV DNA viral load

Beyond the preview

Go deeper on Cytomegalovirus phosphoprotein 65 (pp65) peptide presented by HLA-A02:01 (CMV pp65/HLA-A02:01).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytomegalovirus phosphoprotein 65 (pp65) peptide presented by HLA-A*02:01 (CMV pp65/HLA-A*02:01).

Explore the full profile